Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ategrity Q1 2026 Earnings Call - Record Underwriting Margins and Aggressive Regional Expansion Drive Profitable Growth
Ategrity delivered a second consecutive quarter of record earnings, generating adjusted net income of $25.6 million and a combined ratio of 87.4%. The company grew gross written premiums by 23.1%, sig...
- Ategrity reported adjusted net income of $25.6 million, a sharp increase from $8.5 million in the prior year period, driven by top-line growth and expanding underwriting margins.
- Gross written premiums surged 23.1% year-over-year, with casualty premiums growing 27% and property premiums rising 13%, demonstrating broad-based strength across lines of business.
- The combined ratio improved to 87.4% from 90.9% in the prior year, reflecting a 100 basis point improvement in the loss ratio to 58.8% and a 250 basis point improvement in the expense ratio to 28.6%.
- +7 more takeaways
Viavi Solutions Q3 FY2026 Earnings Call - Data Center Momentum and Operating Leverage Drive Beat
Viavi Solutions delivered a decisive beat in fiscal Q3 2026, with revenue of $406.8 million and an operating margin of 21%, both clearing the high end of guidance. The results were fueled by a massive...
- Revenue of $406.8 million surpassed the high end of the $386 million to $400 million guidance range, reflecting a 10.2% sequential and 42.8% year-over-year increase.
- Operating margin expanded to 21%, beating the high end of the 19.2% to 20.2% guidance range and marking a 170 basis point sequential improvement.
- Non-GAAP EPS of $0.27 exceeded the high end of the $0.22 to $0.24 guidance range, up $0.05 sequentially and $0.12 year-over-year.
- +9 more takeaways
Viking Therapeutics Q1 2026 Earnings Call - Both VANQUISH Trials Fully Enrolled, Oral VK2735 Phase III Deferred to Q4 2026
Viking Therapeutics completed enrollment in both phase III VANQUISH trials for its dual GLP-1/GIP agonist VK2735 and advanced its oral tablet formulation into phase III development, now slated for lat...
- Both VANQUISH-1 (obesity) and VANQUISH-2 (obesity plus type 2 diabetes) trials for subcutaneous VK2735 are fully enrolled, with patient demographics to be presented at European Congress on Obesity and EASD conferences.
- Oral VK2735 advances to phase III development, now expected to initiate in Q4 2026 due to manufacturing scale-up and supply chain optimization, down from prior Q3 2026 expectations.
- Maintenance dosing study expanded to eight subcutaneous cohorts and deferred oral cohorts to a second part; subcutaneous data expected in Q3 2026 to inform the 52-week VANQUISH extension.
- +7 more takeaways
Ethan Allen Interiors Inc. Q3 FY2026 Earnings Call - Tariffs and Government Contracts Weigh on Margins Despite Resilient Retail Demand
Ethan Allen Interiors reported a mixed third quarter for fiscal 2026, with net sales of $136 million driven by higher average ticket prices and clearance activity, offset by a 7.6% decline in wholesal...
- Ethan Allen reported consolidated net sales of $136 million for Q3 FY2026, supported by higher average ticket prices and increased clearance sales, though offset by lower contract sales and reduced delivered unit volume.
- Retail written orders in North America were flat year-over-year, demonstrating resilience despite adverse weather and geopolitical uncertainty, with April trends turning positive.
- Wholesale segment orders declined 7.6%, driven by reduced U.S. State Department business and a slowdown in international operations, leading to a 23% drop in wholesale backlog to $42 million.
- +9 more takeaways
FormFactor Q1 2026 Earnings Call - Record Revenue and Margin Expansion Drive Next Target Model
FormFactor delivered another all-time record in Q1 2026, with revenue reaching $226.1 million and non-GAAP gross margins jumping to 49%, significantly beating the high end of its outlook. The company ...
- Q1 2026 revenue hit a record $226.1 million, exceeding the midpoint of guidance and marking the third consecutive quarter of record sales.
- Non-GAAP gross margins surged to 49%, a 510 basis point sequential increase, significantly beating the high end of the outlook and achieving the company's interim target model.
- Management guided for Q2 2026 revenue of $240 million, indicating a fourth consecutive quarter of record revenue, with non-GAAP gross margins expected to expand further to 49.5%.
- +7 more takeaways
TTM Technologies Q1 2026 Earnings Call - AI & Defense Megatrends Drive Record Revenue and Margin Expansion
TTM Technologies delivered a record-breaking first quarter of 2026, with sales surging 30% year-over-year to $846 million and Non-GAAP EPS climbing 50% to $0.75 per diluted share. The results were fue...
- Sales reached $846 million, a 30% year-over-year increase and an all-time quarterly record, beating prior guidance.
- Non-GAAP EPS rose 50% year-over-year to $0.75 per diluted share, also a record high, driven by favorable product mix and operating leverage.
- Adjusted EBITDA margin expanded to 15.7% from 15.3% in the prior year period, reflecting positive mix impacts and disciplined SG&A management.
- +7 more takeaways
Red Rock Resorts Q1 2026 Earnings Call - Durango Expansion Validates Premium Strategy Despite Construction Headwinds
Red Rock Resorts delivered record Q1 2026 gaming revenue and near-record EBITDA margins, driven by resilient local and regional customer spend. The company navigated temporary headwinds from construct...
- Q1 2026 net revenue reached $507.3 million, up 1.9% year-over-year, with Las Vegas operations contributing $499.5 million.
- Adjusted EBITDA was $212.6 million, down 1.2% year-over-year, with Las Vegas operations at $232.4 million down 1.5%.
- Adjusted EBITDA margin for Las Vegas operations was 46.5%, a decline of 113 basis points year-over-year.
- +7 more takeaways
MiMedx" Q1 2026 Earnings Call - Surgical Growth Offsets Wound Care Collapse Amid Medicare Reimbursement Chaos
MiMedx reported a sharp Q1 2026 result as a chaotic Medicare reimbursement overhaul for skin substitutes slashed wound care sales by 60% year-over-year, while its surgical franchise expanded 13% to be...
- Wound care revenue collapsed 60% year-over-year to $23 million, driven by Medicare’s new fixed-price system, untested prior-authorization tools, and claims-processing freezes that effectively halted market activity.
- Surgical revenue grew 13% to $36 million, marking the first quarter in company history where surgical sales surpassed wound care sales, underscoring a strategic pivot that has delivered 50% top-line growth over three years.
- Full-year 2026 sales guidance was lowered to $260-$290 million, down from prior expectations, as management anticipates a slower-than-expected recovery in the wound care market through the first half of the year.
- +7 more takeaways
CONMED Q1 2026 Earnings Call - Strategic GI Exit Sharpen Focus on AirSeal, Smoke Evacuation, and BioBrace
CONMED delivered a disciplined first quarter, with total sales down 1.3% year-over-year but organic growth of 2.1% after excluding its completed exit from the gastroenterology portfolio. The company d...
- Total sales fell 1.3% year-over-year to $317 million, but organic growth of 2.1% reflects underlying demand after excluding the completed GI portfolio exit.
- AirSeal, the company’s insufflation platform, benefits from an installed base of over 10,000 systems and is gaining share in laparoscopic surgery where penetration remains just 6–7% of U.S. cases.
- Buffalo Filter’s smoke evacuation business faces near-term headwinds from lumpy OEM sales but is supported by 20 U.S. states with smoke-free OR laws covering 51% of the population.
- +9 more takeaways
Aware Q1 FY2026 Earnings Call - Biometric Orchestration Pivot Amid Revenue Miss and Restructuring
Aware reported a disappointing first quarter with revenue of $3.4 million, falling short of expectations as the company acknowledges it underestimated the rapid shift in market demands driven by AI-po...
- Revenue for Q1 FY2026 came in at $3.4 million, down from $3.6 million in the prior year period, missing management's internal expectations.
- CEO Ajay Amlani explicitly admitted the company underestimated the pace of market shifts and the speed at which AI is reshaping biometric infrastructure demands.
- Aware is executing a strategic pivot from a fragmented portfolio of SDKs and components to a unified 'Awareness Platform' focused on biometric orchestration.
- +7 more takeaways